Relative effectiveness of antidepressant treatments in treatment-resistant depression: a systematic review and network meta-analysis of randomized controlled trials
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
This systematic review and network meta-analysis (NMA) sought to compare different antidepressant treatments for treatment-resistant depression (TRD) in order to facilitate evidence-based choices. A literature search of PubMed, Cochrane Library, and Embase from inception until April 13th, 2023 identified randomized, controlled trials (RCTs) of adults with depression who had not responded to at least two antidepressant trials; all RCTs had ≥10 participants per study arm, and participants with bipolar or psychotic depression were excluded. The Cochrane Risk of Bias Tool-2 was used to assess study quality. Response rate was the primary outcome measure. Odds ratios (ORs) using a random effects NMA are reported. From 8234 records, 69 RCTs were included in this analysis, encompassing 10,285 participants (5662 F/4623 M) and 25 separate treatments. Six of the 25 treatments demonstrated a higher response rate versus placebo or sham treatment: electroconvulsive therapy (ECT), minocycline, theta-burst stimulation (TBS), repetitive transcranial magnetic stimulation (rTMS), ketamine, and aripiprazole. ORs ranged from 1.9 (95%CI = [1.25; 2.91]) for aripiprazole to 12.86 (95%CI = [4.07; 40.63]) for ECT. Moderate heterogeneity of the model was observed (I 2 = 47.3% (95%CI [26.8–62%]). Of the included studies, 12.5% were rated as having high risk of bias, 28.13% as having low risk, and 59.38% as showing some concerns. Several effective treatments for TRD showed robust treatment effects across outcomes (ECT, TBS, rTMS, and ketamine), and others showed promising results for some, but not all, outcomes (minocycline, aripiprazole). These findings may help guide evidence-based treatment choices for TRD. Study Registration: PROSPERO (#CRD42023420584).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The evidence regarding quetiapine’s efficacy in TRD varies among studies: earlier meta-analyses reported limited efficacy and noted safety concerns compared to placebo [50], whereas a recent open-label randomized controlled trial indicated potential benefits versus lithium [51].”
From Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials (2025) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Moreover, the approval of quetiapine for TRD was based on an even more lenient definition of resistance, requiring failure of only one prior antidepressant [50].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A., & the PRISMA-P Group (2015) · BMJ · doi:10.1136/bmj.g7647 · Cited by 13,120 · cited 1×
“The study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and its extension statement for NMAs [9].”
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Mutz, J., Vipulananthan, V., Carter, B., Hurlemann, R., Fu, C. H. Y., & Young, A. H. (2019) · BMJ · doi:10.1136/bmj.l1079 · Cited by 427
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408
Self-citationKetamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
Anand, A., Mathew, S. J., Sanacora, G., Murrough, J. W., Goes, F. S., Altinay, M., Aloysi, A. S., Asghar-Ali, A. A., Barnett, B. S., Chang, L. C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302399 · Cited by 276
Zimmerman, M., Posternak, M. A., & Chelminski, I. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.03.007 · Cited by 229 · cited 1×
“To compare the severity of depressive symptoms, a mapping formula was used to convert Hamilton Depression Rating Scale-17 (HAM-D) scores and respective SDs to Montgomery-Asberg Depression Rating Scale (MADRS) scores (MADRS = 1.04×HAM-D17 + 10.13) [10].”
InfluentialEsketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
Reif, A., Bitter, I., Buyze, J., Cebulla, K., Frey, R., Fu, D.-J., Ito, T., Kambarov, Y., Llorca, P.-M., Oliveira-Maia, A. J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304145 · Cited by 222
Nuñez, N. A., Joseph, B., Pahwa, M., Kumar, R., Resendez, M. G., Prokop, L. J., Veldic, M., Seshadri, A., Biernacka, J. M., Frye, M. A., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.134 · Cited by 215
Ren, J., Li, H., Palaniyappan, L., Liu, H., Wang, J., Li, C., & Rossini, P. M. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.02.004 · Cited by 199
Zhou, X., Ravindran, A. V., Qin, B., Del Giovane, C., Li, Q., Bauer, M., Liu, Y., Fang, Y., da Silva, T., Zhang, Y., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14r09204 · Cited by 189
Novel therapeutic targets in depression: Minocycline as a candidate treatment
Soczynska, J. K., Mansur, R. B., Brietzke, E., Swardfager, W., Kennedy, S. H., Woldeyohannes, H. O., Powell, A. M., Manierka, M. S., & McIntyre, R. S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.07.026 · Cited by 189
Psychological therapies for treatment-resistant depression in adults
Ijaz, S., Davies, P., Williams, C. J., Kessler, D., Lewis, G., & Wiles, N. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010558.pub2 · Cited by 155
Nelson, J. C., Baumann, P., Delucchi, K., Joffe, R. T., & Katona, C. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.05.053 · Cited by 141
Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis
Strawbridge, R., Carter, B., Marwood, L., Bandelow, B., Tsapekos, D., Nikolova, V. L., Taylor, R., Mantingh, T., de Angel, V., Patrick, F., et al. (2019) · British Journal of Psychiatry · doi:10.1192/bjp.2018.233 · Cited by 140
Li, H., Cui, L., Li, J., Liu, Y., & Chen, Y. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.03.019 · Cited by 118
Jha, M. K., & Mathew, S. J. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230025 · Cited by 114
Ekstrand, J., Fattah, C., Persson, M., Cheng, T., Nordanskog, P., Åkeson, J., Tingström, A., Lindström, M. B., Nordenskjöld, A., & Movahed Rad, P. (2022) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab088 · Cited by 113
When Should a Trial of Fluoxetine for Major Depression Be Declared Failed?
Quitkin, F. M., Petkova, E., McGrath, P. J., Taylor, B., Beasley, C., Stewart, J., Amsterdam, J., Fava, M., Rosenbaum, J., Reimherr, F., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.734 · Cited by 100
Hellmann-Regen, J., Clemens, V., Grözinger, M., Kornhuber, J., Reif, A., Prvulovic, D., Goya-Maldonado, R., Wiltfang, J., Gruber, O., Schüle, C., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.30367 · Cited by 100
Papadimitropoulou, K., Vossen, C., Karabis, A., Donatti, C., & Kubitz, N. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1277201 · Cited by 91
Efficacy and Mechanisms of Action of Lithium Augmentation in Refractory Major Depression
Bschor, T., & Bauer, M. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206777947650 · Cited by 73
(2019) · Case Medical Research · doi:10.31525/fda2-ucm632761.htm · Cited by 69
Carter, B., Strawbridge, R., Husain, M. I., Jones, B. D. M., Short, R., Cleare, A. J., Tsapekos, D., Patrick, F., Marwood, L., Taylor, R. W., et al. (2020) · International Review of Psychiatry · doi:10.1080/09540261.2020.1765748 · Cited by 47
Mortality risk of antipsychotic augmentation for adult depression
Gerhard, T., Stroup, T. S., Correll, C. U., Setoguchi, S., Strom, B. L., Huang, C., Tan, Z., Crystal, S., & Olfson, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239206 · Cited by 23
Kojic, M., Saelens, J., Kadriu, B., Zarate, C. A., & Kraus, C. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_313 · Cited by 13
Self-citationJumaili, W. A., Vora, D., Trivedi, C. G., & Jain, S. B. (2023) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.22r03467 · Cited by 4
Cited by
Bai, B., Li, Y., Chen, X., Huang, J., Chen, Q., Du, X., Huang, C., & Yang, Y. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06783-7 · Cited by 15
“A meta-analysis investigating anti-depression remedies in treating TRD showed that the response rate of ari-piprazole was significantly higher than placebo [16].”
New insights into the mechanisms of electroconvulsive therapy in treatment-resistant depression
Ruiz, A. C., Haseeb, A., Baumgartner, W., Leung, E., Scaini, G., & Quevedo, J. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1614076 · Cited by 20
Doxycycline: An essential tool for Alzheimer’s disease
Forloni, G. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118159 · Cited by 12
Kang, Y., Jung, J., Han, K., Auer, D. P., & Ham, B. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120607 · Cited by 8
Role of Genetic and Epigenetic Biomarkers in Treatment-Resistant Depression: A Literature Review
Sulić, P., Pavičić, A. R., Ivančić, B. Đ., Božina, T., Božina, N., & Živković, M. (2025) · Genes · doi:10.3390/genes16121443 · Cited by 9
Metadata
- Authors
- Saelens, J., Gramser, A., Watzal, V., Zarate, C. A., Lanzenberger, R., & Kraus, C.
- Affiliations
- Medical University of Vienna (AT)
- National Institutes of Health (US)
- Corresponding author
- Kraus, Christoph
- Venue
- Neuropsychopharmacology
- Published
- 2024-12-30
- Volume
- 50
- Issue
- 6
- Pages
- 913-919
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- PMC
- PMC12032262
- OpenAlex
- W4405890096
- Cited by
- 51
- References
- 26
- Citations by year
- 2026: 35 · 2025: 16
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Neuropsychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (ZIAMH002857)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- treatment-resistant depression, antidepressant treatment, electroconvulsive therapy, minocycline, theta burst stimulation, repetitive transcranial magnetic stimulation, ketamine, aripiprazole, response rate, non-pharmacological depression treatment
- MeSH terms
- Network Meta-Analysis as Topic, Antidepressive Agents, Humans, Randomized Controlled Trials as Topic, Treatment Outcome, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.